Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

August 02, 2017

AbbVie Inc. et al v. Boehringer Ingelheim International GMBH et al

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. May 14, 2019

    Boehringer Waves White Flag In Humira Patent Battle

    Boehringer Ingelheim on Tuesday abandoned its long-shot assault on the patent fortress surrounding AbbVie Inc.'s immunosuppressant Humira, saying it would reluctantly join a long list of biosimilar makers that have agreed to delay competition until 2023.

5 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login